Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3 and suppresses MMP-2 expression

Journal of Pathology

Volumn 202, Issue 1, 2004, Pages 50-59

  Grzmil, Michal ^a   Hemmerlein, Bernhard ^b   Thelen, Paul ^b   Schweyer, Stefan ^b   Burfiend, Peter ^a  

^a Institute of Human Genetics   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Invasion; Laser microdissection; Prostate cancer; Real time RT PCR; Type I IGF receptor

Indexed keywords

ANDROGEN; COMPLEMENTARY RNA; GELATINASE A; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LASER MICRODISSECTION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MATRIX METALLOPROTEINASE 2; MICRODISSECTION; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, ANTISENSE; RNA, NEOPLASM; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0346656569     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1492     Document Type: Review

References (52)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000; 50: 7-33
2. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994; 25: 249-265.
3. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991; 73: 401-407.
4. Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl 1996; 17: 2-4.
5. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996; 93: 7263-7268.
6. DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 3455-3460.
7. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
8. Putz T, Culig Z, Eder IE, et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999; 59: 227-233.
9. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 6276-6280.
10. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787.
11. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995; 136: 5485-5492.
12. Rajah R, Kharo A, Lee PD, Cohen P. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 1999; 163: 487-494.
13. Oh Y, Muller HL, Ng L, Rosenfeld R. Transforming growth factor-β induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270: 13 589-13 592.
14. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-573.
15. Stracke ML, Murata J, Aznavoorian S, Liotta LA. The role of the extracellular matrix in tumor cell metastasis. In Vivo 1994; 8: 49-58.
16. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275: 20 540-20 544.
17. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21 491-21 494.
18. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
19. Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 1998; 58: 3243-3247.
20. Schweyer S, Hemmerlein B, Radzun HJ, Fayyazi A. Continuous recruitment, co-expression of tumor necrosis factor-α and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows Arch 2000; 437: 534-539.
21. Middel P, Thelen P, Blaschke S, et al. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am J Pathol 2001; 159: 1751-1761.
22. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53: 1102-1106.
23. Figueroa JA, Lee AV, Jackson JG, Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995; 80: 3476-3482.
24. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
25. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
26. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106.
27. Oh Y, Muller HL, Ng L, Rosenfeld R. Transforming growth factor-β induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270: 13 589-13 592.
28. 3 and its analog EB1089. Int J Oncol 1998; 13: 137-143.
29. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56: 1545-1550.
30. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996; 271: 1016-1021.
31. Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 1998; 13: 865-869.
32. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000; 60: 5617-5620.
33. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272: 12 181-12 188.
34. Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 1999; 59: 3392-3395.
35. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999; 160: 223-229.
36. Dunn SE, Ehrlich M, Sharp NJH, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998; 58: 3353-3361.
37. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000; 7: 384-395.
38. Tanno S, Tanno T, Mitsuuchi Y, Altomare DA, Xiao G, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001; 61: 589-593.
39. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998; 238: 116-121.
40. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 2001; 276: 33 608-33 615.
41. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
42. Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000; 17: 193-202.
43. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996; 81: 3774-3782.
44. Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155: 1271-1279.
45. Zhang P, Wang-Rodriguez J, Bailey D. Insulin-like growth factor receptor expression in prostate cancer. Am J Clin Pathol 1999; 112: 130.
46. Kurek R, Tunn UW, Aumueller G, Renneberg H. Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor receptor (IGF-R1) in prostate cancer. J Urol 2000; 163: 35 (Suppl).
47. Figueroa JA, De Raad S, Speights VO, Rinehart JJ. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters. Cancer Invest 2001; 19: 28-34.
48. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950.
49. Hampel OZ, Kattan MW, Yang G, et al. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 1998; 159: 2220-2225.
50. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998; 159: 1379-1383.
51. Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytoma. J Clin Oncol 2001; 19: 2189-2200.
52. Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003; 91: 271-277.